CRYOPORT, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CRYOPORT, INC. (CYRX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.40 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- CRYOPORT, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.40M, a 1.18% increase year-over-year.
- CRYOPORT, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $2.40M, a 35.27% decline year-over-year.
- CRYOPORT, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $2.43M, a 44.91% decline year-over-year.
- CRYOPORT, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.53M, a 47.79% decline year-over-year.
- CRYOPORT, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $11.03M, a 44.01% decline from fiscal 2024.
- CRYOPORT, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $19.70M, a 13.61% decline from fiscal 2023.
- CRYOPORT, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $22.81M, a 13.57% increase from fiscal 2022.
- CRYOPORT, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $20.08M, a 30.96% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.40M 10-Q · filed 2026-08-06 | $4.80M 10-Q · filed 2026-08-06 | $7.23M derived: sum of 3 quarters · filed 2026-08-06 | $9.75M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $2.40M 10-Q · filed 2026-05-05 | $4.83M derived: sum of 2 quarters · filed 2026-05-05 | $7.35M derived: sum of 3 quarters · filed 2026-05-05 | $9.73M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.96M derived: sum of 2 quarters · filed 2026-03-05 | $7.33M derived: sum of 3 quarters · filed 2026-08-06 | $11.03M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | $2.53M 10-Q · filed 2025-11-06 | $4.90M derived: sum of 2 quarters · filed 2026-08-06 | $8.60M 10-Q · filed 2025-11-06 | $13.01M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $2.37M 10-Q · filed 2026-08-06 | $6.08M 10-Q · filed 2026-08-06 | $10.49M derived: sum of 3 quarters · filed 2026-08-06 | $15.32M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $3.70M 10-Q · filed 2026-05-05 | $8.11M derived: sum of 2 quarters · filed 2026-05-05 | $12.95M derived: sum of 3 quarters · filed 2026-05-05 | $17.95M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $4.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $9.25M derived: sum of 2 quarters · filed 2026-03-05 | $14.25M derived: sum of 3 quarters · filed 2026-03-05 | $19.70M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | $4.84M 10-Q · filed 2025-11-06 | $9.84M derived: sum of 2 quarters · filed 2025-11-06 | $15.29M 10-Q · filed 2025-11-06 | $21.14M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-06-30 | $5.00M 10-Q · filed 2025-08-12 | $10.45M 10-Q · filed 2025-08-12 | $16.30M derived: sum of 3 quarters · filed 2026-03-05 | $22.28M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-03-31 | $5.46M 10-Q · filed 2025-05-08 | $11.30M derived: sum of 2 quarters · filed 2026-03-05 | $17.28M derived: sum of 3 quarters · filed 2026-03-05 | $23.08M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2023-12-31 | $5.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $11.82M derived: sum of 2 quarters · filed 2026-03-05 | $17.62M derived: sum of 3 quarters · filed 2026-03-05 | $22.81M 10-K · filed 2026-03-05 | ||||
| 2023-09-30 | $5.98M 10-Q · filed 2024-11-07 | $11.78M derived: sum of 2 quarters · filed 2024-11-07 | $16.96M 10-Q · filed 2024-11-07 | $22.29M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2023-06-30 | $5.80M 10-Q · filed 2024-08-08 | $10.98M 10-Q · filed 2024-08-08 | $16.32M derived: sum of 3 quarters · filed 2025-03-07 | $21.68M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2023-03-31 | $5.18M 10-Q · filed 2024-05-08 | $10.52M derived: sum of 2 quarters · filed 2025-03-07 | $15.88M derived: sum of 3 quarters · filed 2025-03-07 | $21.14M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2022-12-31 | $5.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $10.70M derived: sum of 2 quarters · filed 2025-03-07 | $15.96M derived: sum of 3 quarters · filed 2025-03-07 | $20.08M 10-K · filed 2025-03-07 | ||||
| 2022-09-30 | $5.37M 10-Q · filed 2023-11-09 | $10.62M derived: sum of 2 quarters · filed 2023-11-09 | $14.75M 10-Q · filed 2023-11-09 | $18.93M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2022-06-30 | $5.26M 10-Q · filed 2023-08-09 | $9.38M 10-Q · filed 2023-08-09 | $13.57M derived: sum of 3 quarters · filed 2024-03-13 | $17.71M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2022-03-31 | $4.13M 10-Q · filed 2023-05-04 | $8.31M derived: sum of 2 quarters · filed 2024-03-13 | $12.46M derived: sum of 3 quarters · filed 2024-03-13 | $16.48M derived: sum of 4 quarters · filed 2024-03-13 | ||||
| 2021-12-31 | $4.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $8.33M derived: sum of 2 quarters · filed 2024-03-13 | $12.36M derived: sum of 3 quarters · filed 2024-03-13 | $15.33M 10-K · filed 2024-03-13 | ||||
| 2021-09-30 | $4.15M 10-Q · filed 2022-11-04 | $8.17M derived: sum of 2 quarters · filed 2022-11-04 | $11.15M 10-Q · filed 2022-11-04 | $11.15M 10-Q · filed 2021-11-04 | $13.69M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-06-30 | $4.03M 10-Q · filed 2022-08-04 | $7.00M 10-Q · filed 2022-08-04 | $9.54M derived: sum of 3 quarters · filed 2023-02-28 | $9.55M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2021-03-31 | $2.98M 10-Q · filed 2022-05-05 | $5.52M derived: sum of 2 quarters · filed 2023-02-28 | $5.52M derived: sum of 3 quarters · filed 2023-02-28 | $7.80M derived: sum of 4 quarters · filed 2023-02-28 | ||||
| 2020-12-31 | $2.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $2.54M derived: sum of 2 quarters · filed 2023-02-28 | $4.82M derived: sum of 3 quarters · filed 2023-02-28 | $8.83M 10-K · filed 2023-02-28 | ||||
| 2020-09-30 | $2.41K 10-Q · filed 2021-11-04 | $2.41M 10-Q · filed 2020-11-06 | $2.28M derived: sum of 2 quarters · filed 2021-11-04 | $6.29M 10-Q · filed 2021-11-04 | $6.29M 10-Q · filed 2020-11-06 | $5.47M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | $2.28M 10-Q · filed 2021-08-06 | $2.28M 10-Q · filed 2020-08-10 | $3.88M 10-Q · filed 2021-08-06 | $3.88M 10-Q · filed 2020-08-10 | $5.47M derived: sum of 3 quarters · filed 2022-02-28 | $7.40M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | $1.60M 10-Q · filed 2021-05-06 | $1.60M 10-Q · filed 2020-05-08 | $3.19M derived: sum of 2 quarters · filed 2022-02-28 | $5.12M derived: sum of 3 quarters · filed 2022-02-28 | $7.07M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.52M derived: sum of 2 quarters · filed 2022-02-28 | $5.47M derived: sum of 3 quarters · filed 2022-02-28 | $6.87M 10-K · filed 2022-02-28 | $6.87M 10-K · filed 2020-03-10 | |||
| 2019-09-30 | $1.93M 10-Q · filed 2020-11-06 | $3.88M derived: sum of 2 quarters · filed 2020-11-06 | $5.28M 10-Q · filed 2020-11-06 | $6.75M derived: sum of 4 quarters · filed 2020-11-06 | ||||
| 2019-06-30 | $1.96M 10-Q · filed 2020-08-10 | $3.36M 10-Q · filed 2020-08-10 | $4.82M derived: sum of 3 quarters · filed 2020-08-10 | $6.30M derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | $1.40M 10-Q · filed 2020-05-08 | $2.86M derived: sum of 2 quarters · filed 2020-05-08 | $4.34M derived: sum of 3 quarters · filed 2020-05-08 | $5.77M derived: sum of 4 quarters · filed 2020-05-08 | ||||
| 2018-12-31 | $1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $2.95M derived: sum of 2 quarters · filed 2020-03-10 | $4.38M derived: sum of 3 quarters · filed 2020-03-10 | $5.41M 10-K · filed 2020-03-10 | ||||
| 2018-09-30 | $1.48M 10-Q · filed 2019-11-12 | $2.91M derived: sum of 2 quarters · filed 2019-11-12 | $3.94M 10-Q · filed 2019-11-12 | |||||
| 2018-06-30 | $1.43M 10-Q · filed 2019-08-09 | $2.46M 10-Q · filed 2019-08-09 | ||||||
| 2018-03-31 | $1.03M 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | $3.48M 10-K · filed 2019-03-13 | |||||||
| 2016-12-31 | $2.28M 10-K · filed 2018-03-08 | |||||||
| 2016-03-31 | $2.57M 10-KT · filed 2017-03-13 | |||||||
| 2015-03-31 | $864.31K 10-K · filed 2016-06-28 | |||||||
| 2014-03-31 | $678.12K 10-K · filed 2015-05-19 | |||||||
| 2013-03-31 | $693.18K 10-K · filed 2014-06-25 | |||||||
| 2012-03-31 | $281.55K 10-K · filed 2013-06-25 | |||||||
| 2011-03-31 | $971.16K 10-K · filed 2012-06-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |